中国医疗集团(08225.HK)两新药获GMP生产批准
中国医疗集团(08225.HK)公布,公司负责的临床研究开发服务喜恩卡片剂(重酒石酸卡巴拉汀片剂),和重酒石酸卡巴拉汀原料药,在今年获得新药批准後在今年6月5日获得GMP生产批准,其中喜恩卡片是全球第一个上市的独家片剂,国内第一家获得该产品的生产证书,据悉另外两家国产仿制胶囊尚未上市销售。
集团将负责包括喜恩卡、优芝青在内利用RWS-THERAPY和CRCO平台开展上市後真实世界临床研究,相信这将对集团收入产生积极影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.